Risk factor
Strong & resilient to price shocks
Profitability factor
Very strong margins and returns
About
BioGaia AB (publ), a Swedish enterprise founded in 1990 and headquartered in Stockholm, is dedicated to the worldwide development, marketing, and distribution of probiotic products renowned for their scientifically proven health advantages. The company operates through three primary divisions. Its Pediatrics segment offers various items such as drops, oral rehydration solutions, and gut health tablets, in addition to supplying cultures for integration into infant formula. The Adult Health segment provides gut health tablets and oral health lozenges, alongside furnishing cultures to licensees for use in dairy products. A third segment, "Other," specializes in packaging solutions. BioGaia's extensive product portfolio targets a range of health issues, including infantile colic and digestive health in children, antibiotic-associated and acute diarrhea, gingivitis, periodontal disease, general well-being, Helicobacter pylori bacterial infections (linked to gastric ulcers), and concerns related to low bone density. All of its offerings are sold exclusively under the BioGaia brand.
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBITDA, r
Target Price
The average target price of BIOG-B.ST is 165 and suggests 33% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in